Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fadolmidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.59 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fadolmidine SCHEMBL29365481 | 1.00 | ESR1 (0.59) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| Fadolmidine SCHEMBL29489898 | 0.99 | ESR1 (0.58) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| Fadolmidine SCHEMBL2641142 | 0.99 | ESR1 (0.58) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| SCHEMBL7111508 | 0.94 | ESR1 (0.52) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL7038089 | 0.92 | ESR1 (0.51) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| SCHEMBL1339421 | 0.89 | ESR1 (0.59) | ESR1ESR2CYP19A1 | |
| SCHEMBL7034308 | 0.84 | ESR1 (0.40) | ESR1ESR2SLC6A4 | |
| SCHEMBL7153910 | 0.83 | ADRA2A (0.53) | ESR1ESR2DRD2 | |
| SCHEMBL7039816 | 0.83 | ESR1 (0.60) | ESR1ESR2CYP19A1 | |
| SCHEMBL27370373 | 0.81 | ESR1 (0.41) | ESR1ESR2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446025-B2 | Treatment or prevention of hypotension and shock | RECRO PHARMA, INC. (US) | 2016-09-20 | — | — | US | claimed |
| US-20160030392-A1 | Treatment Or Prevention Of Hypotension And Shock | SOCIETAL CDMO, INC. | 2016-02-04 | — | — | US | claimed |
| US-9078883-B2 | Treatment or prevention of hypotension and shock | RECRO PHARMA, INC. (US) | 2015-07-14 | — | — | US | claimed |
| US-20140100257-A1 | TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK | RECRO PHARMA, INC. (US) | 2014-04-10 | — | — | US | claimed |
| US-8470862-B2 | Treatment or prevention of hypotension and shock | RECRO PHARMA, INC. (US) | 2013-06-25 | — | — | US | claimed |
| US-20110294862-A1 | TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK | ORION CORPORATION | 2011-12-01 | — | — | US | claimed |
| JP-4741131-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| US-20070185181-A1 | Treatment or prevention of hypotension and shock | ORION CORPORATION | 2007-08-09 | — | — | US | claimed |
| EP-1223931-B1 | USE OF A IMIDAZOLE DERIVATIVE FOR THE TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK | ORION CORP (FI) | 2005-12-14 | — | — | EP | claimed |
| EP-1117399-B1 | USE OF 3-(1H-IMIDAZOL-4-YLMETHYL)-INDAN-5-OL IN THE MANUFACTURE OF A MEDICAMENT FOR INTRASPINAL, INTRATHECAL OR EPIDURAL ADMINISTRATION | ORION CORP (FI) | 2005-02-09 | — | — | EP | claimed |
| US-6495584-B1 | ANALGESIA TREATMENT | ORION CORPORATION (FI) | 2002-12-17 | — | — | US | claimed |
| JP-2002525324-A | — | — | 2002-08-13 | — | — | JP | claimed |
| EP-1223931-A1 | TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK | ORION CORPORATION (FI) | 2002-07-24 | — | — | EP | claimed |
| US-6313311-B1 | ADRENERGIC STIMULANTS FOR POTENTIATING ANESTHETICS PRIOR TO SURGERY; HYPOTENSIVE AGENTS, ANALGESICS, ANTIISCHEMIC AGENTS; NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | ORION CORPORATION (FI) | 2001-11-06 | — | — | US | claimed |
| EP-1117399-A1 | USE OF 3-(1H-IMIDAZOL-4-YLMETHYL)-INDAN-5-OL IN THE MANUFACTURE OF A MEDICAMENT FOR INTRASPINAL, INTRATHECAL OR EPIDURAL ADMINISTRATION | ORION CORPORATION (FI) | 2001-07-25 | — | — | EP | claimed |
| WO-2001030347-A1 | TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK | ORION CORPORATION (FI) | 2001-05-03 | — | — | WO | claimed |
| WO-2000018400-A1 | USE OF 3-(1H-IMIDAZOL-4-YLMETHYL)-INDAN-5-OL IN THE MANUFACTURE OF A MEDICAMENT FOR INTRASPINAL, INTRATHECAL OR EPIDURAL ADMINISTRATION | ORION CORPORATION (FI) | 2000-04-06 | — | — | WO | claimed |
| US-9446025-B2 | Treatment or prevention of hypotension and shock | RECRO PHARMA, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-5677115-A | DESILVERIZATION; THIOETHER FIXING COMPOUND; DECOLORATION INHIBITION | FUJI PHOTO FILM CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| WO-1997012874-A1 | IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY | Orion-Yhtymä Oy (FI) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030392-A1 | Treatment Or Prevention Of Hypotension And Shock | TNNI3, ADRB3, TNNC1 | ESR1 4863/4885ESR2 4839/4885NQO2 1974/4885 |
| US-20070185181-A1 | Treatment or prevention of hypotension and shock | TNNI3, TNNC1, ADRB3 | ESR1 4870/4885ESR2 4835/4885NQO2 3045/4885 |
| US-20110294862-A1 | TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK | TNNI3, TNNC1, ADRB3 | ESR1 4870/4885ESR2 4835/4885NQO2 3045/4885 |
| US-20140100257-A1 | TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK | TNNI3, ADRB3, TNNC1 | ESR1 4863/4885ESR2 4839/4885NQO2 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.